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To test if spironolactone or dietary nitrate from beetroot juice could reduce arterial 40 
stiffness as aortic pulse wave velocity (PWVart), a potential treatment target, 41 
independently of blood pressure.  42 
Methods 43 
Daily spironolactone (≤50mg) versus doxazosin (control ≤16mg) and 70mL beetroot 44 
juice (‘Beet-It’ ≤11mmol nitrate) versus nitrate-depleted juice (placebo; 0mmol nitrate) 45 
were tested in people at risk or with type-2 diabetes using a double-blind, 6-month 46 
factorial trial. Vascular indices (baseline, 12, 24 weeks) were cardiac-ankle vascular 47 
index (‘CAVI’), a nominally pressure-independent stiffness measure (primary outcome), 48 
pulse wave velocity (PWVart) secondary, central systolic pressure and augmentation. 49 
Analysis was intention-to-treat, adjusted for systolic pressure differences between trial 50 
arms. 51 
Results  52 
Spironolactone did not reduce stiffness, with evidence for reduced CAVI on doxazosin 53 
rather than spironolactone (mean difference [95% confidence intervals]; 0.25[-0.3, 0.5] 54 
units, p=0.080), firmer for PWVart (0.37[0.01, 0.7] ms-1, p=0.045). There was no 55 
difference in systolic pressure reduction between spironolactone and doxazosin (0.7[-56 
4.8, 3.3]mmHg, p=0.7).  Circulating nitrate and nitrite increased on active versus 57 
placebo juice, with central systolic pressure lowered -2.6[-4.5, - 0.8]mmHg, p=0.007 58 
more on the active juice, but did not reduce CAVI, PWVart, nor peripheral pressure.  59 
Change in nitrate and nitrite concentrations were 1.5-fold [1.1-2.2] and 2.2-fold [1.3, 60 




Contrary to our hypothesis, in at-risk/type-2 diabetes patients, spironolactone did not 63 
reduce arterial stiffness, rather PWVart was lower on doxazosin. Dietary nitrate 64 
elevated plasma nitrite, selectively lowering central systolic pressure, observed 65 
previously for nitrite. 66 
 67 
Clinical trial registration: ISRCTN registry: ISRCTN25003627/ DOI 68 
10.1186/ISRCTN25003627. 69 
Statement 1: What is already known about this subject 70 
- Arterial stiffness is a predictor of mortality, independently of BP and diabetes 71 
- Inorganic dietary nitrate has been shown to reduce blood pressure and arterial 72 
stiffness via the nitrate-nitrite, nitric oxide pathway 73 
- Spironolactone is reported to reduce arterial stiffness, but if this is BP-74 
independent is not clear  75 
Statement 2: What this study adds  76 
- The longest trial to test inorganic nitrate on vascular parameters to date 77 
- Inorganic dietary nitrate selectively reduced central systolic BP which parallels 78 
previous data 79 
- Despite lowering BP slightly more than did the -blocker, doxazosin, 80 
spironolactone did not reduce arterial stiffness, which was marginally lowered 81 







Type 2 diabetes mellitus (T2DM) is characterized by excess cardiac and vascular 87 
disease even before ‘formal’ diagnosis [1,2]. Arterial stiffness measured as aortic pulse 88 
wave velocity (PWVart) is amongst the most powerful 21predictors of both 89 
cardiovascular and all-cause mortality, crucially independent of mean or systolic blood 90 
pressure (SBP) and other standard risk factors, including glycaemia [3]. Reducing 91 
arterial stiffness could be particularly valuable in overweight people at increased risk of 92 
or already with overt T2DM, because of its predictive impact in glucose intolerance/ 93 
T2DM [4], and its high prevalence in these people since early measures of arterial 94 
stiffness were used [5-7]. The pathology of arterial stiffness involves elastin degradation 95 
and collagen deposition with fibrosis from inflammatory stimuli including 96 
dysregulation of nitric oxide (NO) [8] and up-regulation of pro-fibrotic factors [9-11]. 97 
 98 
Reductions in PWV by lifestyle measures are reported particularly for exercise, weight 99 
loss and specific dietary components, and by various pharmacological agents, including 100 
anti-hypertensives, statins, some anti-diabetic medications and advanced glycation end-101 
product breakers [12].  However, PWV reduction formally independent of BP is seldom 102 
examined. Doing so is important as PWV is intrinsically linked to BP hence it can be 103 
hard to distinguish the two. 104 
 105 
Spironolactone, a mineralocorticoid receptor antagonist was recently found highly 106 
effective in reducing BP in proven resistant hypertension [13].  Initial trials for 107 
specifically reducing arterial stiffness, in early kidney disease [14], untreated 108 
hypertensives [15] and dilated cardiomyopathy [16] appeared promising. These trials 109 




Inorganic (dietary) nitrate, abundant in green leafy vegetables and beetroot [17] 112 
reduces BP in healthy [18] and hypertensive volunteers [19] via the nitrate-nitrite-NO 113 
pathway [20], but not in patients with T2DM, [21-22] or with their inclusion in a meta-114 
analysis of 24h ambulatory BP monitoring  [23].  PWV reductions with inorganic 115 
(dietary) nitrate have also been noted in healthy and hypertensive volunteers, but over 116 
too short a period for vessel remodelling; these were likely BP-dependent reductions 117 
[24]. We found that inorganic nitrite selectively lowers aortic, relative to peripheral, BP, 118 
with reductions also in PWV that seem to be via selective normoxia-dependent conduit 119 
(radial) artery dilatation in healthy volunteers [25-26], and selectively dilated epicardial 120 
coronary arteries in patients undergoing coronary angiography [27]. While tolerance 121 
develops to organic nitrates [28], it has not been described for inorganic (dietary) 122 
nitrate [19], perhaps this due to the mechanisms of bioactivation of inorganic nitrite to 123 
nitric oxide, and suppression of reactive oxygen species (ROS)[29]. Longer-term effects 124 
of inorganic (dietary) nitrate beyond 6 weeks have not yet been tested. 125 
 126 
In the trial reported here, we hypothesised that spironolactone and dietary nitrate 127 
would reduce arterial stiffness independently of BP reduction in people with or at risk 128 
of T2DM. We tested this hypothesis in a double-blind, controlled, factorial design 24-129 
week trial using cardio-ankle vascular index (CAVI) as the primary measure of stiffness 130 




Study design and interventions 135 
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A single centre, double-blind, parallel, randomised controlled intervention trial in a 2 x 136 
2 factorial design was carried out in accordance with the Declaration of Helsinki and 137 
U.S. Code of Federal Regulations.   138 
Participants were assigned to one of 4 arms using computer randomization in blocks of 139 
6, by an independent party. Interventions were spironolactone (12.5mg daily for 1 140 
week, 12.5mg twice daily for 11 weeks, increased to 25mg twice daily to 24 weeks) with 141 
doxazosin as its control (4mg similarly titrated to 8mg twice daily) and dietary nitrate 142 
as beetroot juice (7.5mmol nitrate increased at 12 weeks to 11.2mmol nitrate, as 143 
measured in our lab) or nitrate-free beetroot juice as placebo (0mmol nitrate), (see 144 
Supplementary text).  Spironolactone and doxazosin were prepared in indistinguishable 145 
brown bottles by St Thomas’ Hospital pharmacy, London, UK.  Commercially available 146 
beetroot juice, ‘Beet It’ and ‘Beet It SPORT’ were supplied as 15 x 70 mL bottles, 147 
indistinguishable between active and control juice, prepared and supplied by James 148 
White Drinks, Ltd, Suffolk UK. 149 
 150 
Participants with or at risk of T2DM were recruited from Guy’s and St Thomas’ 151 
Hospitals, London, UK and surrounding areas between 2013-2015.  Inclusion criteria 152 
were age 18-80years, clinically diagnosed T2DM or at risk of T2DM (as body mass index 153 
(BMI) ≥27 kg/m2, positive family history or glucose intolerance after 75g challenge), 154 
ability to understand and comply with the protocol.  Exclusion criteria: interfering 155 
chronic illness, adverse reaction to either drug, known allergy to beetroot, eGFR < 45 156 
mL min-1, HbA1c >11% (97mM/M), pregnant, breast feeding or atrial fibrillation.  157 
Written informed consent was obtained from all participants.  The protocol was 158 




The primary outcome was change in arterial stiffness, nominally independent of BP, as 161 
measured by CAVI.  Secondary outcomes were arterial stiffness, as measured by 162 
PWVart, with central BP and augmentation index.  Both primary and secondary 163 
outcomes were to be adjusted for differences in peripheral baseline BP and BP change 164 
between trial arms, start-finish.  165 
At St Thomas’ Hospital Clinical Research Facility, London, participants rested supine in 166 
a temperature-controlled room for 20 minutes.  Vascular measures were then 167 
performed supine in random order according to institutional guidelines.  168 
 169 
After anthropometry, CAVI was measured using the VS-1500N, VaSera machine 170 
(Fukuda Denshi Ltd, Japan) as described [30].  Microphone-detected heart sounds were 171 
monitored, with BP cuffs on each arm and above each ankle, with pulse waves detected 172 
by the cuffs at 30-50mmHg. CAVI was calculated from PWV, as pulse wave transit times 173 
from aortic valve (2nd sound) to ankle: CAVI= [ln SBP/ln DBP]. [2ρ/ΔP]. PWV2, with path 174 
length estimated from height [31]. CAVI was measured in duplicate and averaged. CAVI0 175 
data were calculated as described previously [32].  PWVart, peripheral systolic, diastolic 176 
and central BP, aortic and brachial augmentation index and heart rate from 6-8 cardiac 177 
cycles were measured using appropriately sized cuffs by Arteriograph 24TM device 178 
(TensioMed Kft. Hungary), analysing mean of duplicate good quality readings. Quality 179 
was pre-specified with Arteriograph and VaSera waveforms checked by the 180 
manufacturers, blinded to other data. PWV with standard deviations (SDs) >1 were 181 
excluded.   182 
 183 
Non-fasted blood (Hb, HbA1c, plasma glucose, sodium, potassium, creatinine, 184 
aldosterone and renin mass concentrations) and urinary sodium, potassium, creatinine 185 
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were measured by our accredited laboratory.  Plasma nitrate and nitrite concentrations 186 
were measured by chemiluminescence as described [25,33]. 187 
 188 
Statistical analysis 189 
Sufficient data from CAVI interventions were not available for sample size calculations.  190 
We used previous studies on BP with beetroot juice [33-34]and the 1-year study of 191 
PWVart on spironolactone [14] aiming to detect a 20% reduction over 6 months in PWV 192 
(standard deviation (SD) 8%) with minimum 80% power, at p<0.05.  We estimated we 193 
needed 24 participants per each of 4 arms, aiming for 30 per group allowing for 20% 194 
drop out, for 24 patients in each to finish the trial. 195 
 196 
A modified intention-to-treat analysis was performed using SAS (version 9.3); data are 197 
presented as least-square means estimated from mixed effects models (log-transformed 198 
where not normally distributed), adjusted as pre-specified for baseline, and any 199 
difference in final SBP change between the two arms being analysed. To estimate 200 
independence from BP change, changes in PWVart were adjusted for change in SBP. 201 
Least square mean data were averaged over the 2 follow-up visits (3 and 6 months). 202 
Regression analyses assumed linear relationships, with some predictor variables (renin, 203 




Of 154 patients eligible and agreeing to attend, 11 were not eligible (4 for high HbA1c, 2 208 
for previous adverse reactions, 2 with atrial fibrillation, 3 for ill health); 17 then 209 
declined to participate.  The remaining 126 participants were randomised 210 
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(Supplementary Figure 1).  Baseline characteristics were generally well-matched 211 
between arms (Table 1 and Supplementary Table 1) both between drugs and by 212 
nitrate/nitrate-free juices (Tables 2-3).  Of randomized participants, 62% had T2DM 213 
with mean HbA1c 50mM/M (6.7%). The remaining 38% were ‘at risk’ (mean HbA1c 214 
<40 mM/M, 5.8%, BMI 32.5kg/m2).  215 
 216 
Follow up   217 
Time from randomization to midpoint dose increase was 13±3 weeks and from 218 
midpoint-final visit 12±3weeks, totaling 24±5 weeks from randomization to end-of-219 
study. Between baseline and 12 weeks’ follow-up, 16 participants dropped out (6 no 220 
reason, 1 unrelated illness, 4 not re-contacted and 5 with side effects: 2 dizziness, 2 221 
elevated glucose, 1 breathlessness). There were no follow-up measures for these 222 
participants. 223 
 224 
Treatment effects 225 
No statistical interactions occurred between beetroot or placebo juice arms and the 226 
spironolactone vs. doxazosin arm for any of the main/ haemodynamic outcomes, so 227 
data are presented separately (Tables 2-3).  Supplementary Table 1 shows absolute, 228 
unadjusted changes of vascular and biological parameters for the 4 arms. 229 
 230 
SPIRONOLACTONE VS. DOXAZOSIN: In adjusted models, spironolactone and doxazosin 231 
reduced BP similarly (SBP, least-square mean [95% CI]: -7.0 [-9.9, -4.2] vs. -6.3 [-9.1, -232 
3.5] mmHg respectively, p= 0.7, Figure 1C and diastolic (DBP), -5.6 [-7.4, -3.7] vs. -4.7 [-233 
6.5, -2.9] mmHg respectively, p= 0.5, Supplementary Figure 2A). The direction in 234 
difference for the primary endpoint, change in CAVI between drugs, was contrary to our 235 
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hypothesis, borderline significant towards doxazosin (0.14 [-0.06, 0.34] vs. -0.11 [-0.30, 236 
0.08] units p=0.08, for spironolactone and doxazosin respectively, Figure 1A).  When 237 
transposed to CAVI0, our data was not significant -0.04(-0.44, 0.35) vs. 0.24 (-0.19, 238 
0.67), p= 0.34 (doxazosin vs. spironolactone)[19]. However, the difference in PWVart 239 
change between spironolactone and doxazosin was significant (-0.07 [-0.33, 0.18] vs. -240 
0.44 [-0.69, -0.19] ms-2, p=0.045, Figure 1B) towards doxazosin, again contrary to our 241 
hypothesis. There were also no other differences in other hemodynamic parameters 242 
estimated by the Arteriograph for the drug arm, in central BP (-7.6 [-9.0, -6.3] vs. -7.2 [-243 
8.5, -5.9] mmHg, p=0.6; Figure 1 D), augmentation index (Supplementary Figure 2 B-C), 244 
or heart rate.  245 
Although no drug/ juice interactions in terms of hemodynamic variables were noted, 246 
nitrate and nitrite concentrations were higher on spironolactone than on doxazosin by 247 
1.5-fold [1.1-2.2] and 2.2-fold [1.3, 3.6] respectively; both p<0.05; see Figure 1 E-F.  248 
Unadjusted data are in Supplementary Table 1. 249 
 250 
BEETROOT VS. PLACEBO JUICE: There were no adjusted differences in change in 251 
arterial stiffness change as CAVI (0.02 [-0.18, 0.21] vs. 0.01 [-0.18, 0.21], p=0.98, Figure 252 
2A) CAVI0 0.12(-0.29, 0.53) vs. 0.08(-0.34, 0.50), p= 0.898 (active vs. control) [19] nor 253 
PWVart (-0.23 [-0.48, 0.01] vs. -0.28 [-0.54, -0.03], p=0.8, Figure 2B), nor in 254 
brachial BP between active and placebo juice (SBP, -6.4 [-9.2, -3.6] vs. -6.9 [-9.8, -4.0] 255 
mmHg, p= 0.8, Figure 2C, nor DBP, p= 0.9 (Supplementary Figure 3A). However, 256 
difference in change in central (aortic) SBP between active and control juices was highly 257 
significant (-8.7[-10, -7.4] vs. -6.1[-7.4, -4.8] mmHg, p=0.007, Figure 2D).  Decreases in 258 
aortic (-3 [-5.1, -0.9] vs. -0.3 [-2.4, 1.9] %, p=0.08) and brachial augmentation index (-5.9 259 
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[-10.0, -1.76] vs. -0.49 [-4.72, 3.74] %, p=0.08) were also borderline (Supplementary 260 
Figure 3B-C).   261 
Plasma nitrate levels rose as expected in those on active compared with placebo juice (a 262 
4.3[3.4, 5.5]-fold increase vs. 1.3[1.02, 1.71], p<0.001, Figure 2 E); nitrite levels 263 
increased 1.6[1.1, 2.2]-fold vs. 0.9[0.6, 1.2], p=0.02, Figure 2 F). These data confirm 264 
adherence to the beetroot juice arm. Unadjusted data are in Supplementary Table 1. 265 
 266 
Adverse effects 267 
From randomization, all adverse effects were documented and assessed after 268 
unblinding, which did not occur until after the trial finished.  Of 126 participants 269 
randomized, 12 reported effects deemed to be related to the drug interventions (5 270 
dizziness of whom 4 taking doxazosin, 2 rashes (1 taking spironolactone), 1 reported 271 
incontinence (doxazosin), nausea (spironolactone), heartburn (spironolactone), 272 
tachycardia (doxazosin), breathlessness (spironolactone)).  In 8 of these patients, doses 273 
were adjusted or stopped; one participant willingly tolerated the effects.  Throughout 274 
the study 5 patients withdrew consent due to adverse effects, 3 deemed related to the 275 
intervention (2 dizziness, 1 breathlessness); 1 patient reported dyspepsia, deemed 276 
related to juice.  No participants were excluded.   277 
 278 
Further regression analyses 279 
Relationships between baseline plasma renin, nitrate and nitrite and change in CAVI, 280 
PWVart and central BP (from baseline to follow-up) were examined. Change in central 281 
BP was significantly related to baseline plasma renin (r= 0.36, p<0.001), so that for a 282 
10-fold reduction in plasma renin, there was an 8.6 mmHg greater fall in central BP 283 
(Figure 3C).  This result was not specific to either the drug or juice arm.  There were no 284 
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relationships between change in CAVI or PWVart and renin (r=0.02, p=0.8, and r=0.05, 285 
p= 0.6, respectively - Figure 3A-B).  There were also no relationships between change in 286 
CAVI, PWVart or central BP and nitrate (Supplementary Figure 4 A-C; r=0.07, p=0.6; r= -287 
0.04, p= 0.7; r=0.01, p=0.9, respectively) or nitrite (Supplementary Figure 5A-C; r=0.13, 288 




This randomized trial demonstrated a proof of concept that reduction of arterial 293 
stiffness, an independent predictor of mortality generally and in T2DM [4], could be 294 
measured and estimated independently of BP, as measured by CAVI and PWVart, 295 
adjusting for differences in achieved BP between trial groups.  296 
Spironolactone versus doxazosin 297 
The reduction in CAVI, which measures cardiac-ankle PWV, including a long more 298 
muscular arterial path, was borderline (p=0.07). However, contrary to our hypothesis, 299 
the result was in the opposite direction, towards the doxazosin, not the spironolactone 300 
arm. The consistency and direction of this effect on arterial stiffness was supported, 301 
again independent of BP change, by the significant impact on central PWVart, our other 302 
main outcome. Unlike aortic PWV measured as carotid-femoral [3] or down just the 303 
descending aorta [6], PWV in the extremities, down muscular arterial pathways such as 304 
the femoral- posterior tibial or cardiac-brachial routes, does not predict outcomes [34]. 305 
However, the ease of CAVI/ PWV measurement using the multi-cuff arm-ankle method, 306 
which includes the central aorta, and the microphone-detected 2nd sound timing for the 307 
precise initiation of the pressure/flow wave outweighs issues of including extremity 308 
pathways in its measurements. BP independence of CAVI has been discussed and re-309 
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formulated to produce CAVI0 [32,36]; when we transposed our data based on CAVI0 310 
suggested by Spronk et al they were not significant [37]. 311 
 312 
Here, adequate daily doses of ≤16 mg doxazosin, as alpha receptor blockade, were 313 
compared with ≤50 mg spironolactone, as mineralocorticoid receptor antagonist. Our 314 
results contrast with previous work, which suggested spironolactone at just 25 mg 315 
reduced PWV by 0.8 m/s versus placebo, apparently with little change in BP 14, in 316 
patients with mild kidney impairment; in that study, spironolactone had been added to 317 
angiotensin converting enzyme inhibitors and angiotensin receptor blockers. While the 318 
change in PWV and aortic distensibility was significant, so also was the change in either 319 
24-hour ambulatory, or in office systolic BP; i.e.: one was not independent of the other.  320 
Left ventricular (LV) mass also changed, likely in response to the decrease BP. In our 321 
study, we found that LV mass index between the 2 active BP drugs was not significant 322 
[38]. Here, 71% patients were on prior anti-hypertensive medication of many types, and 323 
the 62% with T2DM generally on metformin and other glucocentric agents.  The 324 
difference in change of (office) BP was not significant, despite adjusting for the small 325 
change in favour of spironolactone. Although there are suggestions that doxazosin may 326 
reduce arterial stiffness [39-40], neither of those studies was a formal trial nor adjusted 327 
for any BP change, and its use in arterial function has not to our knowledge been 328 
examined in T2DM. From a physiological point of view the action of doxazosin can be 329 
easily explained. Vascular tone does influence arterial stiffness in muscular arteries [41-330 
42] and is likely to have a similar action in larger arteries (although this influence is 331 




The absolute reduction in BP for those who finished 6 months’ treatment was a similar 334 
7 mmHg SBP reduction in both drug groups, but the least square mean fall in BP was a 335 
non-significantly greater 2.3 mmHg on spironolactone than doxazosin, using a higher 336 
dose than in our recent blinded, rotational Pathway Trial where the difference was 4.5 337 
mmHg [13]. The different patient population and the lower dose of doxazosin likely 338 
contributed to different treatment responses there to here. 339 
 340 
Results from the anti-hypertensive ALLHAT Trial are relevant; its doxazosin arm had to 341 
be stopped after ~2 years, due to excess heart failure and other cardiac events [43]. 342 
Having diabetes on doxazosin in the trial was a particular aggravating factor [44]. 343 
Whilst the change in PWVart and the borderline change in CAVI could be related to 344 
changes in cardiac function, our echocardiographic data [38] do not suggest that as the 345 
ejection fraction (EF), and global longitudinal strain (GLS) which is a well established 346 
markers of systolic function, were similar between the two drugs  in our study; 347 
however, S’ (a tissue-Doppler systolic function index) was increased by spironolactone 348 
versus doxazosin. Thus, while our data suggest we have shown ‘proof of concept’ that 349 
PWVart can be reduced independent of BP change, we have not shown it is independent 350 
of cardiac functional change.  351 
Effects of inorganic nitrate 352 
No effect of active (nitrate containing) beetroot juice, even at higher dose, was found on 353 
peripheral (brachial) BP, CAVI or PWV consistent with two previous dietary nitrate 354 
studies in patients with diabetes [21-22] and in line with our recent results that acute 355 
physiological elevations of plasma glucose and insulin, following an oral glucose 356 
tolerance test, result in a lack of BP-lowering with dietary nitrate in healthy adults [45]. 357 
Previous reductions in PWV were with peripheral BP reductions [22]; the lack of change 358 
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in peripheral BP with nitrate may underlie the lack of effect on PWV, suggesting dietary 359 
nitrate has no direct effect on arterial stiffness. Further the lack of reduction on PWV 360 
with dietary nitrate is in line with acute effects seen previously with glyceryl trinitrate 361 
[46]. Plasma nitrate and nitrite did increase, some 4-fold and only 2-fold respectively. 362 
The two other diabetes studies [21-22] also found significant increases in plasma nitrite 363 
similar to that in healthy participants [33] and hypertensives [19].  364 
 365 
Central SBP decreased on nitrate-containing juice, with similar if borderline changes in 366 
augmentation index, simultaneous to the significant rise in plasma nitrite, without 367 
peripheral BP changes. Although this could be as a result of venodilation with reduced 368 
preload, indeed decreased central SBP was observed with decreased preload (induced 369 
by lower limb venous occlusion) [47], in an echocardiogram sub-study (data not 370 
presented here), we saw only very small differences in stroke volume between 371 
treatments and so, although it might be contributory this is unlikely to be an alternative 372 
mechanism [38]. This selective central SBP change is entirely consistent with our 373 
previous findings of normoxia-dependent conduit artery dilatation after inorganic 374 
nitrite, selectively reducing central SBP [28]. A measurable increase in plasma nitrite in 375 
healthy volunteers also led to decreased brachial-femoral PWV, independently of 376 
peripheral BP [28]. A different more muscular brachial conduit artery arterial path was 377 
studied there. However, whether currently measured central BP has clinical impact 378 
beyond peripheral BP in the general population, as some claim [48], remains uncertain, 379 
as recently reported from Framingham [49], in part related to calibration issues [50-380 
51]. However, central aortic pressure may be especially relevant in specific populations, 381 
such as HFpEF [52].  382 
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The confirmation of a central BP effect here, as found previously, suggests that testing 383 
for central aortic stiffening changes, affecting the aortic root, ascending aorta or arch 384 
using other imaging methods including MR could be revealing. Other recent 385 
Framingham work confirms that rather than flow-mediated dilation per se, poorer 386 
forearm hyperemic mean blood flow velocity reflecting microvascular (smaller 387 
resistance vessel) changes underlies some 8-13% of the overall stiffening effect 388 
measured by PWV that predicts outcomes powerfully and independently of BP in that 389 
cohort [53].  390 
 391 
Despite observing no drug/ juice interactions in hemodynamic parameters, there was 392 
an interesting finding of increased plasma nitrate and nitrite concentrations observed 393 
on spironolactone versus doxazosin. This could be related to spironolactone’s diuretic 394 
effect, hemo-concentrating nitrate and nitrite, relative to the vasodilatory effect of 395 
doxazosin, or via altering renal nitrate/nitrite excretion; unfortunately the latter was 396 
not assessed in this study.  397 
 398 
 399 
Adverse events attributable to the blinded interventions were small and minor, with 400 
one person mentioning some increased reflux/acidity on the active, nitrate containing 401 
beetroot juice. Potassium retention on spironolactone was not a problem at all, 402 
probably because entry excluded people with eGFR values of <45mL.min.  403 
 404 
This was intentionally a pragmatic trial testing general efficacy of the interventions. In 405 
retrospect, the choice of doxazosin as the control antihypertensive agent for 406 
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spironolactone could be disputed, but few other drugs currently balance dosage and 407 
effect equivalently. Medication timing over the 6 months, and adherence to respective 408 
treatments could not be assured, although changes in nitrate concentrations on active 409 
juice suggested reasonable adherence to the juice overall. Participants were asked to 410 
take their treatment and juice on rising or around breakfast-time, since peak plasma 411 
nitrite concentrations after dietary nitrate ingestion occurs about 2.5 hours later [18]; 412 
however, the intervals between juice ingestion and visits to the Clinical Research 413 
Facility and hence blood collection may have been highly variable. Measurements were 414 
all made under standardized conditions in a Clinical Research Facility. We also 415 
recognize the limitation in our sample size calculation being based on PWV, and not 416 
CAVI, the primary outcome of the research; this was due to sufficient data not being 417 
available at the time of starting the trial. 418 
 419 
Contrary to our hypothesis, arterial stiffness was not reduced on spironolactone, rather 420 
that occurred on the doxazosin arm independently of BP, as measured by PWVart, with 421 
a similar borderline effect on the longer muscular arterial pathway estimated by CAVI, 422 
in these patients with or at risk of T2DM. Whilst active nitrate-containing beetroot juice 423 
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Table 1. Mean (with standard deviation) baseline characteristics of patients 619 
randomized into the VaSera trial 620 









Age, years 56.9 (13.9) 56.3 (11.0) 57.6 (12.3) 55.9 (14.0) 
Female, n (%) 11 (31.4) 11 (36.7) 13 (44.8) 11 (33.3) 
Weight, kg 96.4 (15.0) 94.8 (15.2) 98.1 (19.7) 88.4 (19.9) 
Height, m 1.69 (0.10) 1.70 (0.10) 1.71 (0.10) 1.72 (0.12) 
BMI, kg/m2 33.9 (4.9) 33.0 (4.8) 33.3 (6.1) 30.2 (6.1) 
Waist, cm 112 (29) 110 (10) 112 (13) 103 (14) 
T2DM, n (%) 18 (51.4) 20 (66.7) 18 (62.1) 22 (66.7) 
eGFR, mL/min/1.73m2 a 81 (25) 80 (17) 84(23) 84 (18) 
Patients treated with     
Metformin, n (%) 12 (36.4) 15 (50.0) 15 (51.7) 15 (46.9) 
Insulin, n (%)  5 (14.7) 8 (26.7) 2 ( 6.9) 8 (24.2) 
Other oral diabetic medication, 
n (%)  
6 (17.6) 7 (23.3) 7 (24.1) 6 (18.2) 
Anti hypertensive, n (%) b 20 (57.1) 20 (66.7) 25 (86.2) 24 (72.7) 
Mean number of 
antihypertensives, n (%)c 
1.6 (0.7) 1.9 (0.9) 1.7 (0.8) 1.7 (0.6) 
Diuretics, n (%)  5 (14.7) 10 (33.3) 9 (31.0) 13 (40.6) 
Statins, n (%) 15 (44.1) 15 (50.0) 17 (58.6) 15 (45.5) 
 621 
‘Active’ is nitrate containing beetroot juice; ‘placebo’ is nitrate depleted beetroot juice.  622 
2 
 
Values are mean (standard deviation) unless stated otherwise. a Calculated using abbreviated MDRD 623 
equation, b represents those taking at least one anti hypertensive, c represents mean number of anti 624 
hypertensive drugs taken of those taking at least one 625 
3 
 
Table 2.  Mean (with 95% confidence interval) vascular, plasma and urine parameters at baseline and follow-up visits for 626 
spironolactone and doxazosin 627 
 
Baseline Midpoint End 
Spironolactone Doxazosin Spironolactone Doxazosin Spironolactone Doxazosin 
Vascular       
CAVI, units 8.35(8.02,8.67) 8.07(7.68,8.47) 8.37(8.08,8.67) 8.05(7.57,8.52) 8.19(7.81,8.57) 8.04(7.56,8.52) 
PWVart, ms-2 9.4(8.9,9.9) 9.7(9.1,10.2) 9.3(8.8,9.7) 8.9(8.4,9.4) 9.3(8.9,9.7) 9.3(8.8,9.9) 
SBP, mmHg 143.4(138.3,148.4) 140.1(136.2,144.0) 137.2(132.4,141.9) 136.7(132.1,141.3) 135.0(131.1,139.0) 137.7(132.7,142.7) 
DBP, mmHg 88.0(84.7,91.2) 86.8(84.7,88.9) 84.5(81.8,87.1) 84.5(82.0,87.1) 82.6(79.5,85.7) 84.8(82.0,87.7) 
aoSBP, mmHg 135.4(129.1,141.6) 130.0(123.7,136.3) 126.6(120.5,132.7) 125.0(119.5,130.5) 123.7(118.3,129.2) 123.9(119.2,128.6) 
brAIX, % -16.4(-24.8,-7.9) -22.7(-31.6,-13.8) -22.4(-30.2,-14.6) -22.6(-32.7,-12.4) -24.6(-32.9,-16.2) -24.2(-32.7,-15.7) 
aoAIX, % 29.4(25.1,33.6) 26.1(21.6,30.6) 26.3(22.3,30.2) 26.2(21.1,31.4) 25.2(21.0,29.4) 25.4(21.1,29.7) 
HR, bpm 69.9(66.6,73.2) 71.7(68.2,75.2) 69.3(66.4,72.1) 69.6(66.5,72.6) 71.4(68.2,74.5) 69.6(66.3,72.9) 
Plasma       
Glucosea, mmol/L 6.4(5.8,7.0) 6.2(5.6,6.8) 7.1(6.3,8.0) 6.3(5.6,7.2) 6.7(5.8,7.8) 6.0(5.3,6.8) 
HbA1ca, % 6.7(6.3,7.0) 6.7(6.4,7.0) 6.9(6.6,7.3) 6.7(6.4,7.1) 6.8(6.4,7.2) 6.7(6.3,7.1) 




Baseline Midpoint End 
Spironolactone Doxazosin Spironolactone Doxazosin Spironolactone Doxazosin 
Potassium, mmol/L 4.27(4.16,4.39) 4.18(4.07,4.30) 4.53(4.42,4.64) 4.21(4.09,4.34) 4.60(4.49,4.72) 4.17(4.07,4.28) 
Creatininea μmol/L 81.6(76.6,87.0) 81.4(75.9,87.3) 83.1(77.4,89.3) 83.7(78.5,89.2) 84.7(78.5,91.4) 83.4(78.0,89.1) 
Renina, mU/mL 31.8(18.7,54.0) 31.5(20.2,49.2) 63.2(38.5,103.7) 38.3(21.6,67.9) 66.1(39.3,111.4) 39.2(22.1,69.8) 
Aldosteronea,  pmol/L  225(191,264) 229(199,264) 439(367,525) 281(241,327) 391(325,470) 300(251,358) 
Nitratea, μM 37.4(29.6,47.4) 25.2(19.0,33.6) 78.1(55.8,109.4) 62.4(43.5,89.5) 97.8(66.5,144.0) 54.2(35.9,81.9) 
Nitritea, nM 0.189(0.123,0.289) 0.147(0.098,0.222) 0.268(0.177,0.405) 0.133(0.076,0.233) 0.242(0.146,0.400) 0.115(0.065,0.203) 
Urine       
Sodiuma, mmol/L 61.9(53.1,72.2) 64.0(52.7,77.8) 64.1(53.8,76.4) 64.6(53.1,78.5) 78.3(65.5,93.5) 70.0(58.8,83.5) 
Potassiuma, mmol/L 50.4(43.4,58.5) 57.2(48.3,67.8) 66.1(56.5,77.5) 62.5(53.3,73.3) 61.6(52.0,73.0) 70.2(60.8,81.0) 
Creatininea, mmol/L 7.99(6.60,9.68) 9.21(7.45,11.38) 8.86(7.34,10.70) 10.57(8.53,13.08) 8.09(6.71,9.75) 10.58(8.77,12.76) 
*Analyzed in log units and geometric means presented. 
PWVart, pulse wave velocity by Arteriograph; aoSBP, aortic blood pressure; aoAix aortic augmentation index; bpm, beats per minute; brAix, 
brachial augmentation index; CAVI, cardio-ankle vascular index; DBP, diastolic blood pressure; HR heart rate; SBP, systolic blood pressure. Values 





Table 3.  Mean (with 95% confidence interval) vascular, plasma and urine parameters at baseline and two follow up visits for nitrate 629 
containing (active) and nitrate depleted (placebo) beetroot juice 630 
 
Baseline Midpoint End 
Active Placebo Active Placebo Active Placebo 
Vascular       
CAVI, units 8.28(7.92,8.64) 8.14(7.77,8.51) 8.29(7.91,8.67) 8.13(7.72,8.54) 8.15(7.71,8.58) 8.08(7.65,8.52) 
PWVart, ms-2 9.7(9.1,10.3) 9.4(8.9,9.8) 9.3(8.8,9.8) 8.9(8.5,9.4) 9.5(9.0,9.9) 9.2(8.7,9.7) 
SBP, mmHg 142.5(137.7,147.3) 140.9(136.7,145.1) 137.5(132.8,142.3) 136.4(131.7,141.1) 136.2(131.9,140.4) 136.7(131.9,141.5) 
DBP, mmHg 88.5(85.6,91.5) 86.3(83.8,88.7) 84.4(81.5,87.2) 84.6(82.2,87.0) 83.4(80.7,86.1) 84.1(80.9,87.3) 
aoSBP, mmHg 134.8(128.8,140.8) 130.6(124.0,137.1) 127.2(121.1,133.4) 124.4(118.9,129.9) 123.9(119.2,128.5) 123.8(118.3,129.2) 
brAIX, % -13.5(-21.5,-5.5) -25.7(-34.8,-16.6) -20.4(-28.7,-12.2) -24.5(-34.1,-14.8) -23.2(-31.4,-15.0) -25.6(-34.3,-16.9) 
aoAIX, % 30.8(26.7,34.9) 24.6(20.0,29.2) 27.3(23.1,31.5) 25.3(20.4,30.1) 25.9(21.8,30.0) 24.7(20.3,29.1) 
HR, bpm 68.5(65.5,71.5) 73.0(69.3,76.7) 68.8(66.0,71.7) 69.9(66.9,73.0) 71.8(68.6,75.1) 69.1(66.0,72.2) 
Plasma       
Glucosea mmol/L 5.91(5.36,6.52) 6.64(6.05,7.29) 7.04(6.15,8.05) 6.45(5.76,7.21) 6.49(5.66,7.45) 6.21(5.44,7.08) 




Baseline Midpoint End 
Active Placebo Active Placebo Active Placebo 
Sodium, mmol/L 139.9(139.2,140.5) 139.5(138.8,140.2) 138.8(138.0,139.7) 139.3(138.6,140.1) 139.1(138.2,140.0) 139.0(138.1,139.8) 
Potassium, mmol/L 4.26(4.15,4.37) 4.20(4.08,4.33) 4.46(4.32,4.59) 4.32(4.20,4.43) 4.41(4.28,4.55) 4.38(4.26,4.49) 
Creatininea μmol/L 81.3(75.4,87.6) 81.7(77.1,86.7) 83.4(77.1,90.3) 83.4(78.8,88.2) 85.3(78.6,92.5) 82.9(78.1,87.9) 
Renin†, mU/mL 23.5(14.7,37.6) 42.6(26.0,69.8) 41.6(24.7,70.0) 57.4(33.0,99.7) 49.8(29.6,83.7) 54.7(30.4,98.6) 
Aldosteronea,  pmol/L  230(200,266) 224(190,263) 337(281,406) 363(305,431) 375(318,442) 319(260,391) 
Nitratea, μM 28.8(22.5,36.9) 32.4(24.2,43.4) 125.4(94.0,167.3) 43.4(32.5,58.1) 118.0(82.4,169.0) 35.9(25.7,50.0) 
Nitritea, nM 0.191(0.130,0.282) 0.144(0.092,0.226) 0.268(0.168,0.428) 0.139(0.083,0.233) 0.219(0.135,0.353) 0.107(0.056,0.203) 
Urine       
Sodiuma, mmol/L 66.2(54.4,80.6) 60.0(51.7,69.6) 66.9(54.9,81.5) 61.8(52.0,73.3) 79.7(67.3,94.3) 68.9(57.3,82.9) 
Potassiuma, mmol/L 51.6(44.2,60.1) 55.4(47.0,65.3) 63.0(53.2,74.7) 65.3(56.3,75.8) 65.8(56.9,76.0) 65.6(55.1,78.1) 
Creatininea, mmol/L 8.96(7.35,10.93) 8.18(6.67,10.03) 9.58(7.82,11.73) 9.77(7.97,11.98) 9.28(7.68,11.22) 9.12(7.51,11.06) 
*Analyzed in log units and geometric means presented 
 ‘Active’ is nitrate containing beetroot juice; ‘placebo’ is nitrate depleted beetroot juice. PWVart, pulse wave velocity by Arteriograph; aoSBP, aortic blood pressure; 631 
aoAix aortic augmentation index; bpm, beats per minute; brAix, brachial augmentation index; CAVI, cardio-ankle vascular index; DBP, diastolic blood pressure; HR 632 
heart rate; SBP, systolic blood pressure. Values are mean (95% confidence interval)633 
7 
 
FIGURE LEGENDS 634 
Figure 1.  Change in vascular parameters in response to spironolactone and 635 
doxasozin 636 
Change in cardio-ankle vascular index, aortic pulse wave velocity, systolic, and 637 
central blood pressure and plasma nitrate and nitrite concentration on drug 638 
intervention 639 
Data are least square means averaged over the two follow up visits with mean, 95% confidence 640 
intervals.  * is p<0.05. A, CAVI  (cardio-ankle vascular index), B, PWV (pulse wave velocity by 641 
Arteriograph), C, SBP (systolic blood pressure), D, aoSBP (aortic systolic blood pressure), E, 642 
[nitrate] (plasma nitrate concentration), F, [nitrite] (plasma nitrite concentration). 643 
 644 
Figure 2.  Change in vascular parameters in response to inorganic nitrate from 645 
beetroot juice and nitrate free, placebo beetroot juice 646 
Change in cardio-ankle vascular index, aortic pulse wave velocity, systolic, and 647 
central blood pressure, aortic and brachial augmentation index and plasma 648 
nitrate and nitrite concentration on juice intervention. 649 
Data are least square means averaged over the two follow up visits with mean, 95% confidence 650 
intervals.  * is p>0.05, ** is p< 0.01, *** is p<0.001. A, CAVI  (cardio-ankle vascular index), B, PWV 651 
(pulse wave velocity by Arteriograh), C, SBP (systolic blood pressure), D, aoSBP (aortic systolic 652 
blood pressure), E, [nitrate] (plasma nitrate concentration) F, [nitrite] (plasma nitrite 653 
concentration). 654 
 655 
Figure 3. Correlation between change in vascular parameters and baseline 656 
plasma renin 657 




PWV (pulse wave velocity by Arteriograph), BP (blood pressure), CAVI (cardio-ankle vascular 660 
index), n=64. 661 
 662 
 663 
  664 
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